PriceTargets.com logo

Chinook Therapeutics - KDNY Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $37.25
  • Forecasted Upside: -7.77%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 10 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$40.39 As of 08/11/2023 01:00 AM ET
+0 (0.00%)
Get New Chinook Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KDNY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KDNY

Analyst Price Target is $37.25
▼ -7.77% Downside Potential
This price target is based on 11 analysts offering 12 month price targets for Chinook Therapeutics in the last 3 months. The average price target is $37.25, with a high forecast of $42.00 and a low forecast of $32.00. The average price target represents a -7.77% upside from the last price of $40.39.

This chart shows the closing price for KDNY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 11 polled investment analysts is to hold stock in Chinook Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/8/2023WedbushDowngradeOutperform ➝ Neutral$42.00Low
8/1/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$30.00 ➝ $40.00Low
6/14/2023Evercore ISIDowngradeOutperformLow
6/13/2023SVB LeerinkDowngradeOutperform ➝ Market PerformLow
6/13/2023Stifel NicolausDowngradeBuy ➝ HoldLow
6/13/2023HC WainwrightDowngradeBuy ➝ NeutralLow
6/13/2023SVB SecuritiesDowngradeOutperform ➝ Market PerformLow
6/12/2023Bloom BurtonDowngradeBuy ➝ HoldLow
6/12/2023GuggenheimDowngradeBuy ➝ NeutralLow
6/12/2023Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
6/12/2023William BlairDowngradeOutperform ➝ Market PerformLow
5/10/2023HC WainwrightBoost Target$31.00 ➝ $32.00N/A
5/2/2023GuggenheimLower Target$43.00 ➝ $35.00Low
3/6/2023Piper SandlerInitiated CoverageOverweight$41.00Low
2/28/2023GuggenheimInitiated CoverageBuy$43.00Low
2/28/2023OppenheimerBoost TargetOutperform$33.00 ➝ $34.00Low
2/28/2023HC WainwrightLower TargetBuy$33.00 ➝ $31.00Low
2/21/2023OppenheimerBoost TargetOutperform$28.00 ➝ $33.00Low
12/22/2022Stifel NicolausBoost TargetBuy$30.00 ➝ $43.00Low
12/5/2022Wells Fargo & CompanyInitiated CoverageOverweight$30.00Low
11/23/2022HC WainwrightBoost Target$32.00 ➝ $33.00Low
11/17/2022Cantor FitzgeraldReiterated RatingOverweightLow
11/11/2022WedbushReiterated RatingOutperformLow
8/15/2022HC WainwrightBoost TargetBuy$28.00 ➝ $32.00Low
6/27/2022Stifel NicolausInitiated CoverageBuy$30.00Low
5/23/2022SVB LeerinkBoost TargetOutperform$38.00 ➝ $44.00High
12/2/2021SVB LeerinkReiterated RatingBuyMedium
10/18/2021Cantor FitzgeraldReiterated RatingOverweightMedium
6/14/2021Bloom BurtonReiterated RatingBuy$40.00Low
3/22/2021Bloom BurtonReiterated RatingBuyHigh
1/6/2021WedbushInitiated CoverageOutperform$28.00N/A
12/9/2020Cantor FitzgeraldInitiated CoverageOverweight$31.00Low
11/16/2020HC WainwrightInitiated CoverageBuy$28.00High
11/2/2020Evercore ISIInitiated CoverageOutperform$32.00Medium
10/20/2020OppenheimerUpgradeMarket Perform ➝ Outperform$25.00High
10/7/2020SVB LeerinkInitiated CoverageOutperform$38.00High
10/6/2020William BlairReiterated RatingOutperformHigh
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Chinook Therapeutics logo
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.
Read More

Today's Range

Now: $40.39
Low: $40.39
High: $40.39

50 Day Range

MA: $39.86
Low: $38.66
High: $40.39

52 Week Range

Now: $40.39
Low: $18.34
High: $40.51

Volume

N/A

Average Volume

1,186,257 shs

Market Capitalization

$2.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Chinook Therapeutics?

The following Wall Street sell-side analysts have issued reports on Chinook Therapeutics in the last twelve months: Bloom Burton, Cantor Fitzgerald, Evercore ISI, Guggenheim, HC Wainwright, Stifel Nicolaus, SVB Leerink LLC, SVB Securities, Wedbush, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for KDNY.

What is the current price target for Chinook Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Chinook Therapeutics in the last year. Their average twelve-month price target is $37.25, suggesting a possible downside of 7.8%. Wedbush has the highest price target set, predicting KDNY will reach $42.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $32.00 for Chinook Therapeutics in the next year.
View the latest price targets for KDNY.

What is the current consensus analyst rating for Chinook Therapeutics?

Chinook Therapeutics currently has 10 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in KDNY, but not buy more shares or sell existing shares.
View the latest ratings for KDNY.

What other companies compete with Chinook Therapeutics?

Other companies that are similar to Chinook Therapeutics include 89bio, Bio-Techne, Arcellx, Apogee Therapeutics and IDEAYA Biosciences. Learn More about companies similar to Chinook Therapeutics.

How do I contact Chinook Therapeutics' investor relations team?

Chinook Therapeutics' physical mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The company's listed phone number is (206) 485-7241 and its investor relations email address is [email protected]. The official website for Chinook Therapeutics is chinooktx.com. Learn More about contacing Chinook Therapeutics investor relations.